From biomarker discovery and liquid biopsy analysis to AI-guided drug design and companion diagnostics, we apply machine learning to the full spectrum of diagnostic and therapeutic challenges.
The gap between biological data generation and clinical insight has widened dramatically. AI bridges this gap by extracting patterns from complex multi-omics data, predicting drug-target interactions, and enabling earlier, more accurate diagnoses.
High-throughput omics platforms generate massive datasets, but identifying clinically relevant biomarkers from thousands of candidates requires computational approaches that go beyond manual analysis.
Traditional drug development timelines span decades with high attrition rates. ML-driven approaches reduce candidate screening burden and predict drug-likeness early in the pipeline.
Many diseases are diagnosed at advanced stages when treatment options are limited. AI-powered liquid biopsy and imaging analysis enable non-invasive early detection with higher sensitivity.
Precision medicine requires diagnostic tests that predict patient response to specific therapies. AI helps identify molecular signatures that guide treatment selection.
Therapeutic antibodies must satisfy constraints on affinity, specificity, developability, and immunogenicity simultaneously — a multi-objective optimization problem well-suited to computational approaches.
Clinical decision-making requires combining genomic, proteomic, imaging, and clinical data. AI models excel at integrating heterogeneous data sources into unified diagnostic frameworks.
We apply AI across the full diagnostic and therapeutic development pipeline, from early biomarker discovery to preclinical drug candidate design.
We apply multi-omics integration, network analysis, and ML feature selection to identify disease-associated biomarkers from genomics, transcriptomics, proteomics, and metabolomics data. Our pipeline prioritizes candidates based on biological relevance, detectability, and clinical utility.
Using protein language models and structure-based design tools, we engineer therapeutic antibody candidates with optimized affinity, specificity, and developability. Our approach reduces the screening burden from millions to hundreds of candidates.
Our computational pipeline combines virtual screening, molecular generation, and ADMET prediction to identify small-molecule drug candidates with higher probability of clinical success. ML models trained on known drug-target interactions guide hit identification and lead optimization.
We develop AI-driven diagnostic assays that identify patients most likely to benefit from specific therapies. By analyzing patient molecular profiles against treatment response databases, we build predictive models that support precision treatment decisions.
Our diagnostics and therapeutics platform integrates computational design with experimental validation. We combine proprietary ML models, curated biological databases, and wet lab expertise to deliver clinically actionable results.
Unified analysis pipelines that combine genomics, transcriptomics, proteomics, and clinical data into coherent diagnostic models.
Computational predictions are tested experimentally within weeks, with results feeding back to improve model accuracy for the next design round.
Validation protocols designed to meet regulatory standards, with statistical rigor and reproducibility built into every project phase.
A structured approach that moves from data analysis and model development through experimental validation to clinical-ready deliverables.
Define diagnostic or therapeutic objectives, data availability, regulatory context, and success criteria.
Aggregate and preprocess multi-omics, clinical, and literature data into unified analytical datasets.
Train and validate ML models for biomarker identification, drug-target prediction, or antibody design.
Test top candidates experimentally — affinity assays, activity screens, or diagnostic performance evaluation.
Deliver validated biomarker panels, antibody candidates, or diagnostic assays with documentation.
Our methodologies are grounded in peer-reviewed research in AI-driven diagnostics, drug discovery, and precision medicine.
Stokes JM, Yang K, Swanson K et al. "A deep learning approach to antibiotic discovery." Cell. 2020;180(4):688–702.
PMID 32084340Zhang K, Yang X, Wang Y et al. "Artificial intelligence in drug development." Nature Medicine. 2025;31:45–59.
DOI: 10.1038/s41591-024-03434-4Ginghina O, Hudita A, Zamfir M et al. "Liquid biopsy and artificial intelligence as tools to detect signatures of colorectal malignancies: a modern approach in patient's stratification." Frontiers in Oncology. 2022;12:856575.
PMID 35356214Common questions about AI-driven diagnostics and therapeutic development projects.
We work across biomarker modalities including genomic variants, gene expression signatures, protein biomarkers, metabolite profiles, and circulating tumor DNA. Projects range from exploratory discovery to clinical assay development with regulatory support.
Yes. We use protein language models and structure-guided design to generate de novo antibody candidates against your target. The pipeline includes CDR design, humanization, developability assessment, and affinity optimization — all validated experimentally.
We can work with de-identified clinical datasets under appropriate data sharing agreements. All patient data is handled in compliance with applicable regulations. We support both retrospective cohort analysis and prospective study design.
Timelines depend on data availability, complexity, and validation requirements. Exploratory biomarker identification typically takes 2–4 months. Full development with experimental validation and diagnostic assay design may take 6–12 months.
We support companion diagnostic development by building predictive models that link molecular profiles to treatment response. We provide assay design guidance, analytical validation support, and documentation suitable for regulatory submissions.
Share your project goals and data landscape. We'll propose an AI strategy tailored to your clinical and research objectives.
Tell us about your project and we'll get back within 24 hours.
